These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32083004)

  • 1. The
    Yeh LY; Yang CC; Wu HL; Kao SY; Liu CJ; Chen YF; Lin SC; Chang KW
    Front Oncol; 2020; 10():47. PubMed ID: 32083004
    [No Abstract]   [Full Text] [Related]  

  • 2. MiR-106b regulates the apoptosis and tumorigenesis of hepatocellular carcinoma via targeting Zinc finger and BTB domain-containing protein 7A (Zbtb7a).
    Liang X; Zhao Q; Geng T; Luo S; He Q
    J Biochem Mol Toxicol; 2018 Aug; 32(8):e22169. PubMed ID: 29975452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low nuclear zinc finger and BTB domain containing 7A expression is an independent prognostic factor for recurrence-free survival in invasive ductal carcinoma of the breast.
    Kim Y; Kim HS; Do SI
    Int J Clin Exp Pathol; 2018; 11(4):2193-2200. PubMed ID: 31938331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Zinc Finger and BTB Domain-containing 7A in Colorectal Carcinoma.
    Joo JW; Kim HS; Do SI; Sung JY
    Anticancer Res; 2018 May; 38(5):2787-2792. PubMed ID: 29715100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Zbtb7a proto-oncogene as a novel target for miR-125a.
    Hojo N; Tatsumi N; Moriguchi N; Matsumura A; Morimoto S; Nakata J; Fujiki F; Nishida S; Nakajima H; Tsuboi A; Oka Y; Hosen N; Hayashi S; Sugiyama H; Oji Y
    Mol Carcinog; 2016 Dec; 55(12):2001-2009. PubMed ID: 26713860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-125b suppresses oral oncogenicity by targeting the anti-oxidative gene PRXL2A.
    Chen YF; Wei YY; Yang CC; Liu CJ; Yeh LY; Chou CH; Chang KW; Lin SC
    Redox Biol; 2019 Apr; 22():101140. PubMed ID: 30785086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of miR-187 modulates the advances of oral carcinoma by targeting BARX2 tumor suppressor.
    Lin SC; Kao SY; Chang JC; Liu YC; Yu EH; Tseng SH; Liu CJ; Chang KW
    Oncotarget; 2016 Sep; 7(38):61355-61365. PubMed ID: 27542258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer.
    Apostolopoulou K; Pateras IS; Evangelou K; Tsantoulis PK; Liontos M; Kittas C; Tiniakos DG; Kotsinas A; Cordon-Cardo C; Gorgoulis VG
    J Pathol; 2007 Nov; 213(3):294-302. PubMed ID: 17907153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
    Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
    BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis.
    Zhou X; Ren Y; Liu A; Jin R; Jiang Q; Huang Y; Kong L; Wang X; Zhang L
    Sci Rep; 2014 Dec; 4():7461. PubMed ID: 25514838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
    Cai Z; Hao XY; Liu FX
    Arch Oral Biol; 2018 May; 89():20-25. PubMed ID: 29407635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.
    Tseng HY; Chen LH; Ye Y; Tay KH; Jiang CC; Guo ST; Jin L; Hersey P; Zhang XD
    Carcinogenesis; 2012 Oct; 33(10):1871-81. PubMed ID: 22791814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin.
    Shin EC; Seong YR; Kim CH; Kim H; Ahn YS; Kim K; Kim SJ; Hong SS; Park JH
    Exp Mol Med; 2002 May; 34(2):114-22. PubMed ID: 12085986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1.
    Wu B; Lei D; Wang L; Yang X; Jia S; Yang Z; Shan C; Yang X; Zhang C; Lu B
    Am J Cancer Res; 2016; 6(6):1396-407. PubMed ID: 27429852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of ZBTB7A exhibits a tumor suppressive role in gastric cancer cells.
    Sun G; Peng B; Xie Q; Ruan J; Liang X
    Mol Med Rep; 2018 Feb; 17(2):2635-2641. PubMed ID: 29207095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis.
    Chang SM; Hu WW
    J Cell Physiol; 2018 Apr; 233(4):3384-3396. PubMed ID: 28926115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation.
    Carlisi D; D'Anneo A; Angileri L; Lauricella M; Emanuele S; Santulli A; Vento R; Tesoriere G
    J Cell Physiol; 2011 Jun; 226(6):1632-41. PubMed ID: 21413021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.